IMUGENE LIMITED — Capital/Financing Update 2024

Apr 1, 2024

==> picture [177 x 31] intentionally omitted <==

ASX Release

Date: 2 April 2024

– Section 708A(5)(e) disclosure notice Exercise of Restricted Stock Units

Imugene Limited (ASX: IMU) ( Imugene or Company ) has issued 1,439,248 fully paid ordinary shares in respect of the exercise of 1,439,248 Restricted Stock Units, as per the Appendix 2A released today.

Details of the securities issued are as follows:

Class of securities: Ordinary shares ASX Code of the securities: IMU Date of the issue or expected issue of 28 March 2024 the securities: Total number of securities issued or 1,439,248 expected to be issued:

The Company gives notice pursuant to section 708(5)(e) of the Corporations Act 2001 Cth

(Corporations Act) that:

1. the above securities have been issued without disclosure to investors under part 6D.2 Corporations Act;

2. this notice is given under section 708A(5)(e) and in accordance with section 708A(6) Corporations Act;

3. at the date of this notice, the Company has complied with:

4. a. the provisions of chapter 2M Corporations Act as they apply to the Company; and

5. b. sections 674 and 674A Corporations Act; and

6. at the date of this notice, there is no information required to be disclosed by the Company which is ‘excluded information’ (as defined In sections 708A(7) and 708A(8) Corporations Act).

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer

info@imugene.com

Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited

Join us on InvestorHub; investorhub.imugene.com

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and

IMUGENE LIMITED ACN 009 179 551

2

==> picture [42 x 42] intentionally omitted <==

resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Company Secretary, Imugene Limited.

IMUGENE LIMITED ACN 009 179 551

3